Latest Clinical Advances in the Treatment of BRAF V600E-Mutated Metastatic Colorectal Cancer
Host: Scott Kopetz, MD, PhD
Guest: Prof Eric Van Cutsem, MD, PhD
Dr. Scott Kopetz and Prof. Eric Van Cutsem evaluate both the initial and updated pivotal outcomes from the BEACON trial in second- and third-line BRAF V600E-mutated metastatic colorectal cancer. They extend their discussion of these practice-changing results to include the early-stage findings from the ANCHOR trial in the first-line setting. This podcast also highlights the central role of anti-EGFR therapies in the management of patients with BRAF V600E-mutated metastatic colorectal cancer.
Additional downloadable slides will be available soon.